Protalix BioTherapeutics (PLX) Competitors

$2.58 +0.04 (+1.42%)

As of 11:22 AM Eastern

PLX vs. BBOT, ALLO, MNPR, TECX, and CTMX

Should you buy Protalix BioTherapeutics stock or one of its competitors? Protalix BioTherapeutics's main competitors and comparable companies include BridgeBio Oncology Therapeutics (BBOT), Allogene Therapeutics (ALLO), Monopar Therapeutics (MNPR), Tectonic Therapeutic (TECX), and CytomX Therapeutics (CTMX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Protalix BioTherapeutics compare to BridgeBio Oncology Therapeutics?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Protalix BioTherapeutics has higher revenue and earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.76	N/A
Protalix BioTherapeutics	$80.62M	2.57	$8.31M	$0.23	11.20

In the previous week, BridgeBio Oncology Therapeutics had 1 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 1 mentions for BridgeBio Oncology Therapeutics and 0 mentions for Protalix BioTherapeutics. BridgeBio Oncology Therapeutics' average media sentiment score of 0.93 beat Protalix BioTherapeutics' score of 0.00 indicating that BridgeBio Oncology Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
BridgeBio Oncology Therapeutics	Positive
Protalix BioTherapeutics	Neutral

54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are held by company insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

BridgeBio Oncology Therapeutics has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat BridgeBio Oncology Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Oncology Therapeutics	N/A	-46.90%	-42.17%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

BridgeBio Oncology Therapeutics currently has a consensus price target of $24.40, indicating a potential upside of 185.71%. Protalix BioTherapeutics has a consensus price target of $12.00, indicating a potential upside of 365.84%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than BridgeBio Oncology Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

BridgeBio Oncology Therapeutics has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market.

Summary

BridgeBio Oncology Therapeutics beats Protalix BioTherapeutics on 8 of the 15 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Allogene Therapeutics has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-50.04%	-36.74%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Protalix BioTherapeutics has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	34,289.88	-$190.89M	-$0.67	N/A
Protalix BioTherapeutics	$80.62M	2.57	$8.31M	$0.23	11.20

In the previous week, Allogene Therapeutics had 13 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 13 mentions for Allogene Therapeutics and 0 mentions for Protalix BioTherapeutics. Allogene Therapeutics' average media sentiment score of 0.92 beat Protalix BioTherapeutics' score of 0.00 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Allogene Therapeutics	Positive
Protalix BioTherapeutics	Neutral

Allogene Therapeutics presently has a consensus target price of $8.30, indicating a potential upside of 318.14%. Protalix BioTherapeutics has a consensus target price of $12.00, indicating a potential upside of 365.84%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Allogene Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Allogene Therapeutics has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of 0.02, indicating that its stock price is 98% less volatile than the broader market.

Summary

Allogene Therapeutics beats Protalix BioTherapeutics on 10 of the 17 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Monopar Therapeutics currently has a consensus price target of $118.67, suggesting a potential upside of 9.18%. Protalix BioTherapeutics has a consensus price target of $12.00, suggesting a potential upside of 365.84%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Protalix BioTherapeutics has higher revenue and earnings than Monopar Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A
Protalix BioTherapeutics	$80.62M	2.57	$8.31M	$0.23	11.20

In the previous week, Monopar Therapeutics had 7 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 7 mentions for Monopar Therapeutics and 0 mentions for Protalix BioTherapeutics. Monopar Therapeutics' average media sentiment score of 0.56 beat Protalix BioTherapeutics' score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Monopar Therapeutics	Positive
Protalix BioTherapeutics	Neutral

Monopar Therapeutics has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market.

Monopar Therapeutics has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Monopar Therapeutics' return on equity of -13.08% beat Protalix BioTherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-13.08%	-12.79%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 9.7% of Monopar Therapeutics shares are held by insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Monopar Therapeutics and Protalix BioTherapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to Tectonic Therapeutic?

Protalix BioTherapeutics (NYSE:PLX) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

In the previous week, Tectonic Therapeutic had 4 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 4 mentions for Tectonic Therapeutic and 0 mentions for Protalix BioTherapeutics. Tectonic Therapeutic's average media sentiment score of 1.10 beat Protalix BioTherapeutics' score of 0.00 indicating that Tectonic Therapeutic is being referred to more favorably in the news media.

Company	Overall Sentiment
Protalix BioTherapeutics	Neutral
Tectonic Therapeutic	Positive

Protalix BioTherapeutics has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.28, meaning that its share price is 228% more volatile than the broader market.

Protalix BioTherapeutics has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$80.62M	2.57	$8.31M	$0.23	11.20
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A

Tectonic Therapeutic has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Tectonic Therapeutic	N/A	-35.26%	-33.59%

Protalix BioTherapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 365.84%. Tectonic Therapeutic has a consensus target price of $77.80, suggesting a potential upside of 150.68%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Protalix BioTherapeutics is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Tectonic Therapeutic	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 6.7% of Protalix BioTherapeutics shares are held by company insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Tectonic Therapeutic beats Protalix BioTherapeutics on 9 of the 16 factors compared between the two stocks.

How does Protalix BioTherapeutics compare to CytomX Therapeutics?

Protalix BioTherapeutics (NYSE:PLX) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 6.7% of Protalix BioTherapeutics shares are held by insiders. Comparatively, 3.8% of CytomX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Protalix BioTherapeutics has higher revenue and earnings than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$80.62M	2.57	$8.31M	$0.23	11.20
CytomX Therapeutics	$76.20M	9.28	-$17.37M	-$0.50	N/A

In the previous week, CytomX Therapeutics had 7 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 7 mentions for CytomX Therapeutics and 0 mentions for Protalix BioTherapeutics. CytomX Therapeutics' average media sentiment score of 0.85 beat Protalix BioTherapeutics' score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Protalix BioTherapeutics	Neutral
CytomX Therapeutics	Positive

Protalix BioTherapeutics has a beta of 0.02, indicating that its stock price is 98% less volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.12, indicating that its stock price is 112% more volatile than the broader market.

Protalix BioTherapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 365.84%. CytomX Therapeutics has a consensus price target of $11.90, suggesting a potential upside of 266.83%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protalix BioTherapeutics is more favorable than CytomX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Protalix BioTherapeutics has a net margin of -21.03% compared to CytomX Therapeutics' net margin of -435.21%. Protalix BioTherapeutics' return on equity of -30.89% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
CytomX Therapeutics	-435.21%	-38.46%	-30.33%

Summary

Protalix BioTherapeutics beats CytomX Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Protalix BioTherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLX vs. The Competition

Export

Metric	Protalix BioTherapeutics	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$207.55M	$3.91B	$7.13B	$24.01B
Dividend Yield	N/A	3.61%	2.54%	3.72%
P/E Ratio	-19.82	11.65	272.81	29.83
Price / Sales	2.57	1,394.01	686.32	16.78
Price / Cash	17.80	44.06	28.74	19.75
Price / Book	5.48	16.74	11.02	4.82
Net Income	$8.31M	-$22.71M	$3.47B	$1.07B
7 Day Performance	6.89%	2.47%	1.11%	-0.87%
1 Month Performance	8.69%	12.45%	8.03%	1.58%
1 Year Performance	66.19%	53.62%	23.69%	12.85%

Protalix BioTherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLX Protalix BioTherapeutics	2.2072 of 5 stars	$2.58 +1.4%	$12.00 +365.8%	+63.9%	$207.55M	$80.62M	N/A	200
BBOT BridgeBio Oncology Therapeutics	2.4905 of 5 stars	$9.37 +2.5%	$24.40 +160.4%	N/A	$751.19M	N/A	N/A	N/A
ALLO Allogene Therapeutics	2.2702 of 5 stars	$2.17 +6.9%	$8.30 +282.5%	+78.8%	$749.71M	$20K	N/A	310
MNPR Monopar Therapeutics	2.32 of 5 stars	$110.82 -0.5%	$118.67 +7.1%	+227.6%	$743.60M	N/A	N/A	10
TECX Tectonic Therapeutic	2.9201 of 5 stars	$37.71 +3.4%	$77.80 +106.3%	+39.5%	$737.23M	N/A	N/A	120	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PLX) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Protalix BioTherapeutics (PLX) Competitors

PLX vs. BBOT, ALLO, MNPR, TECX, and CTMX

How does Protalix BioTherapeutics compare to BridgeBio Oncology Therapeutics?

Summary

How does Protalix BioTherapeutics compare to Allogene Therapeutics?

Summary

How does Protalix BioTherapeutics compare to Monopar Therapeutics?

Summary

How does Protalix BioTherapeutics compare to Tectonic Therapeutic?

Summary

How does Protalix BioTherapeutics compare to CytomX Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX vs. The Competition

Protalix BioTherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Protalix BioTherapeutics (PLX) Competitors

PLX vs. BBOT, ALLO, MNPR, TECX, and CTMX

How does Protalix BioTherapeutics compare to BridgeBio Oncology Therapeutics?

Which has preferable valuation and earnings, BBOT or PLX?

Does the media prefer BBOT or PLX?

Do insiders & institutionals hold more shares of BBOT or PLX?

Is BBOT or PLX more profitable?

Do analysts prefer BBOT or PLX?

Which has more volatility and risk, BBOT or PLX?

Summary

How does Protalix BioTherapeutics compare to Allogene Therapeutics?

Is ALLO or PLX more profitable?

Do institutionals and insiders hold more shares of ALLO or PLX?

Which has better earnings & valuation, ALLO or PLX?

Does the media prefer ALLO or PLX?

Do analysts prefer ALLO or PLX?

Which has more risk & volatility, ALLO or PLX?

Summary

How does Protalix BioTherapeutics compare to Monopar Therapeutics?

Do analysts prefer MNPR or PLX?

Which has higher earnings & valuation, MNPR or PLX?

Does the media prefer MNPR or PLX?

Which has more risk and volatility, MNPR or PLX?

Is MNPR or PLX more profitable?

Do institutionals & insiders have more ownership in MNPR or PLX?

Summary

How does Protalix BioTherapeutics compare to Tectonic Therapeutic?

Does the media favor PLX or TECX?

Which has more volatility & risk, PLX or TECX?

Which has stronger valuation and earnings, PLX or TECX?

Is PLX or TECX more profitable?

Do analysts recommend PLX or TECX?

Do institutionals and insiders have more ownership in PLX or TECX?

Summary

How does Protalix BioTherapeutics compare to CytomX Therapeutics?

Do institutionals & insiders have more ownership in PLX or CTMX?

Which has better earnings and valuation, PLX or CTMX?

Does the media favor PLX or CTMX?

Which has more volatility & risk, PLX or CTMX?

Do analysts rate PLX or CTMX?

Is PLX or CTMX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX vs. The Competition

Protalix BioTherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools